These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38752627)

  • 21. Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial.
    Kakushima N; Hori K; Ono H; Horimatsu T; Uedo N; Ohata K; Doyama H; Kaneko K; Oda I; Hikichi T; Kawahara Y; Niimi K; Takaki Y; Mizuno M; Yazumi S; Hosokawa A; Imagawa A; Niimi M; Yoshimura K; Muto M
    J Gastroenterol; 2016 Feb; 51(2):104-11. PubMed ID: 25940151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations.
    Vakil N; Niklasson A; Denison H; Rydén A
    BMC Gastroenterol; 2014 Oct; 14():177. PubMed ID: 25304129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease.
    Hershcovici T; Jha LK; Gadam R; Cui H; Gerson L; Thomson S; Fass R
    J Clin Gastroenterol; 2012 Sep; 46(8):662-8. PubMed ID: 22858518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint.
    Scherr D; Khairy P; Miyazaki S; Aurillac-Lavignolle V; Pascale P; Wilton SB; Ramoul K; Komatsu Y; Roten L; Jadidi A; Linton N; Pedersen M; Daly M; O'Neill M; Knecht S; Weerasooriya R; Rostock T; Manninger M; Cochet H; Shah AJ; Yeim S; Denis A; Derval N; Hocini M; Sacher F; Haissaguerre M; Jais P
    Circ Arrhythm Electrophysiol; 2015 Feb; 8(1):18-24. PubMed ID: 25528745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Female Sex on Clinical Outcomes in the FIRE AND ICE Trial of Catheter Ablation for Atrial Fibrillation.
    Kuck KH; Brugada J; Fürnkranz A; Chun KRJ; Metzner A; Ouyang F; Schlüter M; Elvan A; Braegelmann KM; Kueffer FJ; Arentz T; Albenque JP; Kühne M; Sticherling C; Tondo C;
    Circ Arrhythm Electrophysiol; 2018 May; 11(5):e006204. PubMed ID: 29700058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
    Franciosi JP; Mougey EB; Williams A; Gomez Suarez RA; Thomas C; Creech CL; George K; Corao D; Lima JJ
    Eur J Pediatr; 2018 Jan; 177(1):69-77. PubMed ID: 29209919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Sci Rep; 2020 Jan; 10(1):769. PubMed ID: 31964957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endoscopic treatment of proton pump inhibitor-refractory gastroesophageal reflux disease with anti-reflux mucosectomy: Experience of 109 cases.
    Sumi K; Inoue H; Kobayashi Y; Iwaya Y; Abad MRA; Fujiyoshi Y; Shimamura Y; Ikeda H; Onimaru M
    Dig Endosc; 2021 Mar; 33(3):347-354. PubMed ID: 32415898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate.
    Derejko P; Polańska M; Chojnowska L; Michałowska I; Wójcik A; Piotrowicz E; Lech A; Kłopotowski M; Baranowski R; Przybylski A; Bilińska M; Sierpiński R; Walczak F; Szumowski L
    Kardiol Pol; 2013; 71(1):17-24. PubMed ID: 23348529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease in non-responders to proton pump inhibitors.
    Hamdy E; El Nakeeb A; Hamed H; El Hemaly M; ElHak NG
    J Gastrointest Surg; 2014 Sep; 18(9):1557-62. PubMed ID: 24985244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endoscopic management of gastroesophageal reflux disease: Panacea for proton pump inhibitors dependent/refractory patients.
    Kalapala R; Singla N; Reddy DN
    Dig Endosc; 2022 May; 34(4):687-699. PubMed ID: 34651353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
    J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Yadlapati R; DeLay K
    Med Clin North Am; 2019 Jan; 103(1):15-27. PubMed ID: 30466671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow up in patients with gastroesophageal reflux disease with specific emphasis on reflux symptoms, use of anti-reflux medication and anti-reflux surgery outcome: a retrospective study.
    Van Meer S; Bogte A; Siersema PD
    Scand J Gastroenterol; 2013 Nov; 48(11):1242-8. PubMed ID: 24041112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is the proton pump inhibitor test helpful in patients with laryngeal symptoms?
    Kim JH; Sung IK; Hong SN; Lee SY; Park HS; Shim CS
    Dig Dis Sci; 2013 Jun; 58(6):1663-7. PubMed ID: 23443492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
    Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
    J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of residual gastric acid secretion with persistent symptoms in gastroesophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy.
    Kikuchi H; Fukuda S; Koike T; Shimodaira Y; Watanabe K; Saito M; Nakagawa K; Hatta W; Masamune A; Iijima K
    Esophagus; 2021 Apr; 18(2):380-387. PubMed ID: 32737802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.